Certara Releases Phoenix™ Drug Development Software Version 8.5

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-based drug development, today announced the release of Phoenix™ Version 8.5. Phoenix is ​​the pharmaceutical industry’s gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The Phoenix platform is used by more than 75 of the world’s top 100 pharmaceutical companies. Eleven regulatory agencies, including the U.S. FDA, Japan’s PMDA, and China’s NMPA, rely on Phoenix to evaluate life-saving drug candidates. Version 8.5 is the latest release of Certara’s Phoenix platform, available as a hosted solution for maximum performance and lowest total cost of ownership.

Today, 88% of new medicines Clinical trials fail, signaling the need for process improvements. Certara’s Phoenix platform streamlines everything from data preparation to reporting – a time-consuming process that drug developers rely on.

“Certara develops software solutions that transform research data into reliable information for scientists and regulators with the goal of bringing new medicines to market more quickly.” said Max Kanevsky, Chief Technology Officer at Certara. “The latest release of Phoenix includes new capabilities requested by existing customers and their IT business partners that streamline the end-to-end PK/PD data workflow.”

Version 8.5 offers New features driven by customer demand. These features improve the efficiency, quality and speed of PK/PD workflows in Phoenix.

• Login via Certain Cloud – Phoenix 8.5 introduces user login via Certara Central Admin, which offers single sign-on and centralized authentication. This simplifies license management, streamlines assignments, improves access control, and enhances the user experience by providing easier access to resources, training, and support.
• Reporting improvements for tables, charts, and reports: The updates are designed to offer greater customization and efficiency in the presentation of data in tables and charts, along with advanced capabilities for visual data analysis. These enhancements are intended to streamline the reporting process and enable more detailed and easily interpretable reports.
• NLME (nonlinear mixed effects) improvements: Phoenix National Football Championship is a population modeling and simulation software solution for scientists with a variety of experience levels, from novice PK/PD scientists to the most advanced modelers. The 8.5 update improves modeling accuracy, increases scalability for users, and provides tools to enhance model interpretability.

Developed with feedback from customers participating in Phoenix’s Customer Advisory Board and User Group communities, Phoenix 8.5 will improve user access and experience, enabling more effective data analysis, interpretation, and visualization. For more information, visit https://www.certara.com/software/phoenix-pkpd/.

About Certara

Certara accelerates drug production by using biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include more than 2,400 biopharmaceutical companies, academic institutions and regulatory agencies in 66 countries. Learn more at certara.com.

Certara Contact:
Sheila Rocchio
[email protected]

Press contact:

Alyssa Horowitz
[email protected]